| abstract |
Disclosed is a pharmaceutical composition which is useful as a therapeutic agent for fatty liver diseases. The pharmaceutical composition comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4- fluorophenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, or (1S)-1,5-anhydro-1-[4-(chloro-3-(4- ethoxybenzyl)phenyl)-D-glucitol or a pharmaceutically acceptable salt thereof. The pharmaceutical composition can be used for the treatment of fatty liver diseases, specifically non-alcoholic fatty liver diseases, more specifically non-alcoholic simple steatosis and/or non-alcoholic steatohepatitis. |